Desenvolvimento e caracterização de comprimidos mucoadesivos para tratamento de Helicobacter pylori.

• Ano de defesa: 2023
• Autor(a) principal: Maísa Angélica Silva Fernandes
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Minas Gerais; Brasil; FARMACIA - FACULDADE DE FARMACIA; Programa de Pós-Graduação em Ciências Farmacêuticas; UFMG
• Palavras-chave em Português: Helicobacter pylori; Polímero; Comprimido; Mucoadesivo
• Link de acesso: http://hdl.handle.net/1843/64774

Helicobacter pylori is a bacteria that can cause inflammation and is associated with gastrointestinal problems, including cancer. Treatment is usually based on the association of antibiotics, however, the difficulty in making the drug available at the site of action, among other reasons, has made treatment increasingly difficult. The development of adhesive systems is one of the therapies used in this treatment. Given this context, tablets containing clarithromycin with different concentrations of mucoadhesive polymers chitosan and polyvinyl alcohol were developed. The granules were characterized by means of pharmacopeic methods and showed adequate flow and compactability properties for the manufacture of tablets. The produced tablets were characterized by pharmacopoeic tests to determine weight, hardness, friability, uniformity of unit dose and dosage, demonstrating as results, low variability, adequate appearance, resistance and uniformity of dose in accordance with pharmacopoeial standards. The tablets were also characterized using scanning electron microscopy, infrared absorption spectroscopy, X-ray diffraction and differential scanning calorimetry techniques and the results showed that the API and the excipients in the formulation did not show signs of incompatibility, furthermore, the manufacturing process did not change the crystallinity of clarithromycin. Additionally, the dissolution profile and the release model of clarithromycin were evaluated using mathematical models and it was observed that the formulation with the highest concentration of chitosan presented a release mechanism predominantly by diffusion, and the other pills have their release proportional to reduction of its size. Finally, the tablets were evaluated for mucoadhesive properties showing associative interactions demonstrating potential mucoadhesive effectiveness. These results allowed us to conclude that the tablets were developed and characterized effectively and have potential for scalability for the development of drugs for the treatment of Helicobacter pylori.